The PRECISE-DIET Trial

November 9, 2026 updated by: Bettina Ewers, Steno Diabetes Center Copenhagen

Precision Nutrition Versus Standard Dietary Care: Effect of Personalised Nutrition Guidance Based on Continuous Glucose Monitoring in Type 2 Diabetes - The PRECISE-DIET Trial

People with type 2 diabetes receive standard dietary advice to improve glycaemic control. However, blood glucose responses to the same foods can vary considerably between individuals. This randomised controlled trial aims to investigate whether personalised carbohydrate recommendations guided by continuous glucose monitoring (CGM) improve glycaemic control (HbA1c) compared with standard dietary care.

A total of 130 adults with type 2 diabetes will be randomly assigned to one of two groups. The study will include a 6-month intervention period followed by a 6-month follow-up period. The intervention group will receive dietitian-led personalised carbohydrate recommendations informed by CGM data, supplemented by group-based education in carbohydrate counting. The control group will receive standard individual dietary counselling provided by a dietitian without the use of CGM.

The primary outcome is the between-group difference in change in HbA1c from baseline to 6 months.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

130

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Herlev, Denmark, 2730
        • Steno Diabetes Center Copenhagen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • T2D
  • Diabetes duration of ≥12 months
  • Age ≥18 years
  • HbA1c ≥58 mmol/mol
  • Attending the SDCC outpatient clinic
  • Provided voluntary signed informed consent

Exclusion Criteria:

  • Inability to understand the study information
  • Medical complications that prevent lowering HbA1c to below 58 mmol/mol
  • Use of insulin therapy
  • Low daily carbohydrate intake (defined as below 25 E% or 100 g/day) prior to study inclusion
  • Systematic use of corticosteroids
  • Using or requiring a specialised diet (e.g., protein restriction in kidney disease)
  • Circumstances that affect HbA1c (e.g., liver disease and anaemia)
  • Known or suspected drug or alcohol abuse
  • Pregnancy or breastfeeding or plans of pregnancy within the study period
  • Participation in other clinical trials
  • Individuals with a BMI of <27 kg/m²
  • Initiation of GLP-1 receptor agonist or SGLT inhibitor therapy within the previous 3 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Personalised dietary intervention

CGM-supported personalised carbohydrate recommendations

Participants will receive structured, personalised dietary recommendations supported by continuous glucose monitoring (CGM). Initial carbohydrate recommendations will be based on approximately 35% of total energy intake and translated into individual targets expressed as grams of carbohydrate per day and per meal. These targets will be adjusted throughout the intervention based on individual needs and glycaemic responses rather than prescribed as fixed amounts. CGM data will be used to assess individual postprandial glucose responses and guide adjustments to carbohydrate intake and its distribution throughout the day. The intervention will also include education in basic carbohydrate counting and dietitian-led counselling to support the implementation and maintenance of dietary changes.

Active Comparator: Standard dietary counselling

Standard dietary counselling for type 2 diabetes

Participants will receive standard dietary counselling for type 2 diabetes based on current dietary recommendations, without CGM-guided personalisation of carbohydrate intake. The counselling will include one initial 60-minute individual consultation with a dietitian, followed by two 30-minute follow-up consultations.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in HbA1c
Time Frame: Baseline to 6 months

Between-group difference in change in HbA1c (mmol/mol) from baseline to 6 months

Baseline to 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in HbA1c at 12 months
Time Frame: Baseline to 12 weeks and 12 months

Between-group difference in HbA1c change (mmol/mol)

Baseline to 12 weeks and 12 months
Time in range (TIR)
Time Frame: Baseline, 6 and 12 months

Percentage of CGM time with glucose 3.9-10.0 mmol/L

Baseline, 6 and 12 months
Time above range (TAR)
Time Frame: Baseline, 6 and 12 months

Percentage of CGM time with glucose >10.0 mmol/L

Baseline, 6 and 12 months
Time below range (TBR)
Time Frame: Baseline, 6 and 12 months

Percentage of CGM time with glucose <3.9 mmol/L

Baseline, 6 and 12 months
Estimated HbA1c
Time Frame: Baseline, 6 and 12 months

HbA1c estimated from CGM data (mmol/mol)

Baseline, 6 and 12 months
Change in glycaemic variability
Time Frame: Baseline, 6 and 12 months

Coefficient of variation (%) derived from CGM

Baseline, 6 and 12 months
Body mass index (BMI)
Time Frame: Baseline, 6 and 12 months

kg/m²

Baseline, 6 and 12 months
Waist and hip circumference
Time Frame: Baseline, 6 and 12 months

cm

Baseline, 6 and 12 months
Blood pressure
Time Frame: Baseline, 6 and 12 months

Systolic and diastolic (mmHg)

Baseline, 6 and 12 months
plasma glucose
Time Frame: Baseline, 6 and 12 months

mmol/L

Baseline, 6 and 12 months
Plasma insulin
Time Frame: Baseline, 6 and 12 months

pmol/L

Baseline, 6 and 12 months
C-peptide
Time Frame: Baseline, 6 and 12 months

pmol/L

Baseline, 6 and 12 months
Total cholesterol
Time Frame: Baseline, 6 and 12 months

mmol/L

Baseline, 6 and 12 months
LDL cholesterol
Time Frame: Baseline, 6 and 12 months

mmol/L

Baseline, 6 and 12 months
HDL cholesterol
Time Frame: Baseline, 6 and 12 months

mmol/L

Baseline, 6 and 12 months
Triglycerides
Time Frame: Baseline, 6 and 12 months

mmol/L

Baseline, 6 and 12 months
Diabetes distress (questionnaire)
Time Frame: Baseline, 6 and 12 months

Problem Areas in Diabetes (PAID) score

Baseline, 6 and 12 months
Treatment satisfaction (questionnaire)
Time Frame: Baseline, 6 and 12 months

Diabetes Treatment Satisfaction Questionnaire (DTSQ) score

Baseline, 6 and 12 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in glucose-lowering medication
Time Frame: Baseline, 6 and 12 months

Changes in type and dose of glucose-lowering medication

Baseline, 6 and 12 months
Personality traits (questionnaire)
Time Frame: Baseline

Big Five Inventory (BFI-44) scores

Baseline
Dietary intake
Time Frame: Baseline and 6 months

Total energy intake and macronutrient composition from a 3-day food record

Baseline and 6 months
Physical activity
Time Frame: Baseline and 6 months

Physical activity level measured with an AX3 accelerometer worn for 7 days

Baseline and 6 months
Carbohydrate estimation ability (questionnaire)
Time Frame: Baseline, 6 and 12 months

Accuracy of participants' carbohydrate estimates

Baseline, 6 and 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 1, 2027

Primary Completion (Estimated)

September 1, 2028

Study Completion (Estimated)

March 1, 2029

Study Registration Dates

First Submitted

November 9, 2026

First Submitted That Met QC Criteria

November 9, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe